July 27, 2016 7:53 PM ET


Company Overview of Putney, Inc.

Company Overview

Putney, Inc., a pet pharmaceutical company, develops and sells generic prescription medicines for pets. It provides veterinary-approved products, such as Enrofloxacin flavored tablets for use in dogs and cats for the management of diseases associated with bacteria susceptible to Enrofloxacin; Cefpodoxime Proxetil tablets to dogs for the treatment of skin infections (wounds and abscesses); Mupirocin ointment for the topical treatment of canine bacterial infections of the skin; Carprofen caplets to dogs for pain associated with canine osteoarthritis, and for controlling post-operative pain from certain surgeries; and Ketamine HCl for Injection C-III, a nonnarcotic nonbarbiturate agent for anes...

One Monument Square

Suite 400

Portland, ME 04101

United States

Founded in 2006





Key Executives for Putney, Inc.

Founder, Chairman, Chief Executive Officer and President
Vice President of Finance and Controller
Chief Operating Officer
Age: 47
Senior Vice President of Regulatory Policy and Counsel
Vice President of Human Resources
Compensation as of Fiscal Year 2016.

Putney, Inc. Key Developments

Dechra Pharmaceuticals plc, Putney, Inc. - M&A Call

To discuss the acquisition and placing

Putney, Inc. Launches Tiletamine-Zolazepam, First-To-Market Generic of Telazol

Putney, Inc. announced that its Tiletamine-Zolazepam (tiletamine HCl and zolazepam HCl) injectable, the only FDA-approved generic of Zoetis’ Telazol, is now commercially available. Veterinarians can purchase the drug through one of Putney’s network of regional distributors or directly from Putney. National veterinary distributors are prevented from carrying Putney’s Tiletamine-Zolazepam by “exclusive dealing agreements”, so-called in the recent FTC report entitled “Competition in the Pet Medications Industry.

Putney, Inc. Launches Putney Carprofen Chewable Tablets

Putney, Inc. announced that it is launching Putney Carprofen Chewable Tablets, its FDA approved generic of Zoetis’ popular Rimadyl® Chewable Tablets. With this product approval, the company’s fourth in less than three months, Putney is the company with FDA approved generics of all three dosage forms of carprofen products – Putney Carprofen Chewable Tablets, Putney Carprofen Sterile Injectable Solution, and Putney Carprofen Caplets. Putney’s other recent FDA approvals include Putney Dexmedetomidine HCl, a first-to-market generic of Dexdomitor® and the company’s third approval of a first-to-market generic in less than two years. Putney expects to penetrate and expand the $70 million carprofen chewable tablet market rapidly as veterinarians opt to save approximately 30% on Putney’s bioequivalent product (compared to Rimadyl® Chewable Tablets current list price).

Similar Private Companies By Industry

Company Name Region
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States
7 Oaks Pharmaceutical Corp. United States

Recent Private Companies Transactions

March 15, 2016

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Putney, Inc., please visit www.putneyvet.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.